Johnson & Johnson (JNJ) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Johnson & Johnson (JNJ) has a cash flow conversion efficiency ratio of 0.116x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($9.17 Billion) by net assets ($79.28 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See JNJ defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Johnson & Johnson - Cash Flow Conversion Efficiency Trend (1989–2024)
This chart illustrates how Johnson & Johnson's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Johnson & Johnson Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Johnson & Johnson ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tencent Holdings Ltd
F:NNND
|
0.054x |
|
Exxon Mobil Corp
NYSE:XOM
|
0.048x |
|
ASML Holding N.V.
AS:ASML
|
-0.105x |
|
Intel Corporation
NASDAQ:INTC
|
0.009x |
|
ASML Holding NV ADR
NASDAQ:ASML
|
-0.105x |
|
Visa Inc. Class A
NYSE:V
|
0.084x |
|
Oracle Corporation
NYSE:ORCL
|
0.340x |
|
ASML HOLDING NY EO-09
F:ASMF
|
-0.105x |
Annual Cash Flow Conversion Efficiency for Johnson & Johnson (1989–2024)
The table below shows the annual cash flow conversion efficiency of Johnson & Johnson from 1989 to 2024. For the full company profile with market capitalisation and key ratios, see Johnson & Johnson (JNJ) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $71.49 Billion | $24.27 Billion | 0.339x | +2.43% |
| 2023-12-31 | $68.77 Billion | $22.79 Billion | 0.331x | +20.09% |
| 2022-12-31 | $76.80 Billion | $21.19 Billion | 0.276x | -12.74% |
| 2021-12-31 | $74.02 Billion | $23.41 Billion | 0.316x | -14.97% |
| 2020-12-31 | $63.28 Billion | $23.54 Billion | 0.372x | -5.53% |
| 2019-12-31 | $59.47 Billion | $23.42 Billion | 0.394x | +5.97% |
| 2018-12-31 | $59.75 Billion | $22.20 Billion | 0.372x | +6.16% |
| 2017-12-31 | $60.16 Billion | $21.06 Billion | 0.350x | +31.33% |
| 2016-12-31 | $70.42 Billion | $18.77 Billion | 0.267x | -1.64% |
| 2015-12-31 | $71.15 Billion | $19.28 Billion | 0.271x | +1.21% |
| 2014-12-31 | $68.99 Billion | $18.47 Billion | 0.268x | +13.85% |
| 2013-12-31 | $74.05 Billion | $17.41 Billion | 0.235x | -0.99% |
| 2012-12-31 | $64.83 Billion | $15.40 Billion | 0.237x | -5.19% |
| 2011-12-31 | $57.08 Billion | $14.30 Billion | 0.250x | -13.50% |
| 2010-12-31 | $56.58 Billion | $16.39 Billion | 0.290x | -11.59% |
| 2009-12-31 | $50.59 Billion | $16.57 Billion | 0.328x | -6.99% |
| 2008-12-31 | $42.51 Billion | $14.97 Billion | 0.352x | +0.05% |
| 2007-12-31 | $43.32 Billion | $15.25 Billion | 0.352x | -2.86% |
| 2006-12-31 | $39.32 Billion | $14.25 Billion | 0.362x | +18.11% |
| 2005-12-31 | $38.71 Billion | $11.88 Billion | 0.307x | -12.31% |
| 2004-12-31 | $31.81 Billion | $11.13 Billion | 0.350x | -11.27% |
| 2003-12-31 | $26.87 Billion | $10.60 Billion | 0.394x | +9.47% |
| 2002-12-31 | $22.70 Billion | $8.18 Billion | 0.360x | -1.52% |
| 2001-12-31 | $24.23 Billion | $8.86 Billion | 0.366x | +13.67% |
| 2000-12-31 | $20.39 Billion | $6.56 Billion | 0.322x | -8.10% |
| 1999-12-31 | $16.21 Billion | $5.68 Billion | 0.350x | +0.88% |
| 1998-12-31 | $14.08 Billion | $4.89 Billion | 0.347x | -1.23% |
| 1997-12-31 | $12.36 Billion | $4.34 Billion | 0.351x | -2.14% |
| 1996-12-31 | $10.84 Billion | $3.89 Billion | 0.359x | -3.97% |
| 1995-12-31 | $9.04 Billion | $3.38 Billion | 0.374x | -10.49% |
| 1994-12-31 | $7.12 Billion | $2.98 Billion | 0.418x | +7.28% |
| 1993-12-31 | $5.57 Billion | $2.17 Billion | 0.389x | -5.96% |
| 1992-12-31 | $5.17 Billion | $2.14 Billion | 0.414x | +39.07% |
| 1991-12-31 | $5.63 Billion | $1.68 Billion | 0.298x | -11.96% |
| 1990-12-31 | $4.90 Billion | $1.66 Billion | 0.338x | +12.22% |
| 1989-12-31 | $4.15 Billion | $1.25 Billion | 0.301x | -- |
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bow… Read more